GM PHARMA Obtains the License for Production of the Medicine of Spanish Pharmaceutical Company in Georgia

Between the Georgian pharmaceutical company GM PHARMA and the European company Combino Pharm, an important technological transfer of the production of cardiovascular medicine and the "Know-how" agreement was formed.

Combino Pharm belongs to the world-renowned Spanish pharmaceutical company Medichem (https://www.medichem.es), which specializes in the production of solid dosage forms.

Medichem is presented in more than 70 countries and spends 10% of its turnover on research and development (R&D) of new medicines. The company has all the necessary international certificates and permits for production (EU GMP, US FDA), owns several R&D centers and pharmaceutical enterprises in Europe.

Within the collaboration, GM PHARMA will more quickly launch cardiovascular preparations in Georgia and its export countries, which will enable doctors and patients to better manage life-threatening cardiovascular diseases.

According to the GM PHARMA's Chief Operating Officer, Levan Varduashvili, technological transfer and obtaining a production license from a European company is unprecedented not only for the Georgian, but also for the South Caucasus pharmaceutical industry.

This type of business cooperation will allow GM PHARMA to register the medicines produced in its pharmaceutical factory in EU countries, obtain the European Good Manufacturing Practices Certificate (EU GMP) and start active operations in Eastern and Western European countries.

GM PHARMA is an international pharmaceutical company, the medicines and biologically active food supplements (BAD) of which are produced in GMP-certified enterprises of Western European countries (Germany, Spain, Italy, Portugal, Greece, Sweden, Switzerland) and Georgia.